Service for specialized journalists

Grünenthal press release 2013

Welcome to Grünenthal's Press Overview

27 Dec 2013

Grünenthal completes acquisition of Empresas Andrómaco

Aachen / Santiago de Chile, December 27, 2013. The Grünenthal Group today announced the acceptance of the public tender offer with respect to the acquisition of all issued and outstanding shares of Laboratorios Andrómaco S.A. Inversiones Gruchi Limitada, a subsidiary of Grünenthal GmbH, Germany, has acquired 81.59% of all issued and outstanding shares of Laboratorios Andrómaco S.A. through a public tender offer.

More ...

16 Dec 2013

Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®

Aachen, Germany / Redwood City (California), USA – December 16, 2013 – Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self-administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, EEA and Australia. AcelRx will supply Grünenthal with the product and retains all rights in remaining countries including the US and Asia.

More ...

03 Dec 2013

Contract with chairman of Grünenthal Group’s Corporate Executive Board extended

Aachen, Germany, December 2nd 2013. The Grünenthal Group today announced that the supervisory board of the international pharmaceutical company prolonged the contract with the chairman of its Corporate Executive Board, Professor Dr. Eric-Paul Pâques, ahead of time and confirmed him in office as Chief Executive Officer for another three years. Professor Pâques had taken over the leadership of the pain specialist with its international headquarters in Aachen in May this year.

More ...

25 Nov 2013

Grünenthal launches public tender offer to the shareholders of Empresas Andrómaco

  • Offer period from November 25 to December 24, 2013
  • Offer price of CLP 332.48 per share
  • Offer price represents a premium of 66.99% on the closing price of Sept 6
  • Objective is to acquire all outstanding shares via tender offer

More ...

06 Nov 2013

Grünenthal takes over a product portfolio of BIOGEN® LABORATORIOS

Aachen (Germany) / Bogota (Colombia), November 6th 2013. The Grünenthal Group has signed an agreement with the Colombian pharmaceutical company BIOGEN® LABORATORIOS to take over one of its product portfolios including the corresponding trademarks. BIOGEN® LABORATORIOS has been operating in the market for more than thirty years.

More ...

28 Oct 2013

Grünenthal fosters the enhancement of treatment standards for pain in Europe

Aachen, October 28, 2013 – 96 million Europeans suffer from chronic pain.1,2 21% of these people have been affected for more than 20 years. Across Europe chronic pain accounts for nearly 500 million lost working days per year – costing the European economy around € 34 billion.1 However, the average period between initial symptoms of chronic pain disease and the beginning of adequate therapeutic intervention is four years, as shown by a recent study in Germany.3

More ...

12 Oct 2013

CHANGE PAIN initiative supports the International Day Against Pain 2013

Aachen, Germany, October 12, 2013. Today´s third International Day Against Pain is designed to give a voice to people suffering from pain, to provide information about the treatments that are available, to create a global alliance to broadcast the right to treatment and to raise funds for scientific research.

More ...

11 Oct 2013

Think outside the pill box when tackling localized neuropathic pain – latest news and experiences with the targeted topical treatment for patients suffering from post-herpetic neuralgia

Florence, October 11th, 2013. – Worldwide millions of patients are tortured by a pain that is unexplainable for them. In a series of Meet-the-expert sessions hosted by Grünenthal at the 8th EFIC Pain in Europe congress in Florence, Italy, experts explained that in approximately 60% of cases, neuropathic pain is localized affecting a specific circumscribed area of the body.

More ...   

10 Oct 2013

Supporting young scientists is the key in the battle against pain

Florence, October 10th 2013. As the field of pain has evolved significantly in Europe over the years, pain research is more relevant than ever: Every fifth adult citizen in Europe suffers from persistent or chronic pain, so pain has become a major health problem in Europe. In line with the thought that pain research is getting more and more important, the EFIC-Grünenthal Grant (E-G-G) gave young scientists support and a platform in the course of the 8th EFIC® Congress in Florence, Italy.

More ...

10 Oct 2013

Grünenthal presents a new patient education program at the EFIC congress 2013

“Ants crawling under my skin” – pain specialists experience the torture of neuropathic pain patients

Florence, October 10th, 2013 – „It feels like little ants crawling under my skin” or “like hot needles pinching my forearm” described pain specialists, visiting the EFIC congress 2013 in Florence, Italy, the sensations they experienced at the “My pain feels like…” booth. At the Grünenthal sponsored booth area, visitors had the opportunity to experience localized neuropathic pain sensations by putting their forearm in the “My pain feels like…” box, where electrodes were placed on the nerve tracts and mimicked the neuropathic pain stimulus.

More ...

next [10]